Emisphere Technologies, Inc. (OTCMKTS: EMIS) has seen a legendary rise over the past year from lows of $0.34 to recent highs over $8 per share. The stock quickly attracted a massive shareholder base that continues to push this one higher.
EMIS has been around for years and was incorporated in 1986 in Deleware. In January 1992 the Company changed their name from Clinical Technologies Associates, Inc. to Emisphere Technologies, Inc.
Emisphere Technologies, Inc. (OTCMKTS: EMIS) is a drug delivery company that utilizes its proprietary Eligen® Technology to develop new oral formulations of therapeutic agents. Emisphere is currently partners with global pharmaceutical companies for the development of new orally delivered therapeutics. Emisphere launched its first prescription product, oral Eligen B12, in the U.S. in March 2015. Beyond Eligen B12. Emisphere is currently partnered with global pharmaceutical companies for the development of new orally delivered therapeutics.
The Eligen ® Technology is a broadly applicable proprietary oral drug delivery technology based on the use of proprietary synthetic chemical compounds known as Eligen ® delivery agents, or carriers. These carriers facilitate and enable the transport of therapeutic macromolecules (such as proteins, peptides, and polysaccharides) and poorly absorbed small molecules across biological membranes. The Eligen ® Technology not only facilitates absorption, but it acts rapidly in the upper sections of the gastrointestinal tract where absorption is thought to occur.
Using Eligen ® Technology, most therapeutic macromolecules reach the general circulation in less than an hour post-dose, which can limit enzymatic degradation that typically affects macromolecules and may be advantageous in cases where time to onset of action is important (i.e. analgesics). The Eligen ® technology is distinguished from competitive technologies in that absorption takes place through a transcellular pathway, as opposed to passing between cells, preserving the integrity of the tight junctions within the cell walls and reducing the likelihood of inflammatory processes and autoimmune gastrointestinal diseases.
Furthermore, Eligen ® Technology carriers are rapidly absorbed, distributed, metabolized and eliminated from the body, and they do not accumulate in the organs and tissues and are considered safe at anticipated doses and dosing regimens. Drugs or nutritional supplements whose bioavailability is limited by poor membrane permeability or chemical or biological degradation, and which have a moderate-to-wide therapeutic index, appear to be the best candidates for use with the Eligen ® Technology.
To Find out the inside Scoop on EMIS Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
The Eligen ® Technology can be applied to the oral route of administration as well as other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The Eligen ® Technology makes it possible to deliver certain therapeutic molecules orally without altering their chemical form or biological activity. Eligen ® delivery agents, or “carriers”, facilitate or enable the transport of therapeutic molecules across the mucous membranes of the gastrointestinal tract, to reach the tissues of the body where they can exert their intended pharmacological effect. Our development efforts are conducted internally or in collaboration with corporate development partners.
In November EMIS announced the completion and results on Thursday, November 22 and Friday, November 23 regarding their Pioneer 9 and Pioneer 6 phase 3a trials, both conducted with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog. Both studies utilized Emisphere Technologies, Inc. proprietary Eligen® SNAC Carrier Technology. These two clinical trials represent the completion of Novo Nordisk’s ten-study Pioneer phase 3a oral semaglutide clinical program. A copy of the detailed Novo Nordisk’s study announcements on the Pioneer 9 and Pioneer 6.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $496 million market valuation EMIS has $4.6 million in the treasury and a whoppping $160 million in liabilities. The Company is already doing steady sales reporting $222,000 in revenues for the 3 months ended March 31, 2019. In 2017, Emisphere won an $18 million settlement from Eli Lilly & Co. related to a 2006 breach of contract lawsuit. Additional terms of the settlement are confidential. In January 2006, a federal court determined that Eli Lilly breached an agreement with Emisphere by failing to make a $3 million milestone payment, as required upon the completion of oral PTH 1-34 product Phase I studies. The court also ruled that Emisphere could end a license agreement for a drug-delivery technology with Eli Lilly. We will be updating on EMIS when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with EMIS.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in EMIS either long or short and we have not been compensated for this article.